Regeneus FY17 Results Announcement
This financial period has seen the company achieve major milestones that build the foundation for the businesses future success.
Strategic collaboration with AGC of
As part of our
- AGC has the exclusive rights to manufacture Progenza in
- AGC will have a 50% interest in Regeneus Japan, which holds the exclusive rights for the clinical development and commercialisation of Progenza for osteoarthritis and all other clinical indications in
- In
Successful STEP trial results
On 22 May, we announced the positive results from the Phase 1 STEP trial of Progenza in patients with knee osteoarthritis, meeting the primary endpoint of safety and tolerability.
Other key outcomes from the trial were:
- significant, rapid and sustained reduction in knee pain at both Progenza doses
- significant improvement in cartilage volume compared to placebo
- positive signs of disease modification consistent with preclinical results
Other key achievements
Other key achievements for the period include:
- advanced discussions with potential partners for clinical development of Progenza for a range of indications in
- patent allowed in
- patent allowed in EU,
- commenced
- completed a successful Kvax study for treatment of canine osteosarcoma with VCA in the
Financial Highlights
The financial highlights for the reporting period include:
- licence fee revenues up 715% to
- profit of
- R&D tax incentive of
- Quarterly cash used in operations (excluding R&D tax incentive) maintained at
- 30 June cash available
Outlook
Over the next 12-18 months, the company will continue to focus on unlocking value in its clinical-stage human and animal pipeline products through the generation of positive clinical data, technology development and partnering activities including:
- advance clinical partnering discussions for Progenza in
- report on results of ACTIVATE Phase 1 cancer vaccine trial
- report on results of studies for Sygenus stem cell secretions technology
- report on results of CryoShot canine pre-pivotal osteoarthritis trial
To view the Full Year Results presentation, please visit:
http://abnnewswire.net/lnk/Y9AXH71B
To view the 2017 Annual Report, please visit:
http://abnnewswire.net/lnk/J73FH2HD
About
Contact:
Investors: Sandra McIntosh Company Secretary and Investor RelationsRegeneus Ltd T: +61 2 9499 8010 E: Sandra.mcintosh@regeneus.com.au W: www.regeneus.com.au